Fig. 2

Residual tumor cells are quiescent. a Immunofluorescence (IF) staining for Ki67 on sections from H2B-eGFP-labeled orthotopic HER2/neu-Prim1 primary tumors (PT, left) and residual lesions (RL) 28 days (middle) or 56 days (right) after HER2/neu deinduction. b, c IF for BrdU on sections from H2B-eGFP-labeled HER2/neu-Prim1 (b) or Wnt1-Prim1 (c) orthotopic primary tumors (left) or MRLs 28 days after oncogene deinduction (right) in mice labeled with BrdU for 2 weeks prior to sacrifice. d Quantification of H2B-eGFP-labeled tumor cells staining positive for Ki67 in a. e, f Quantification of H2B-eGFP-labeled tumor cells staining positive for BrdU in (b, c), respectively. g, h IF staining for BrdU on sections from H2B-eGFP-labeled orthotopic primary tumors (left), or MRLs 28 days after deinduction (middle) or 72 h following reinduction (right). Mice were labeled with BrdU for 2 h prior to sacrifice. i, j Quantification of H2B-eGFP-labeled tumor cells staining positive for BrdU in (g, h), respectively. Scale bars (a-c, g, h) 50 μm. *p value vs. primary tumor (PT) < 0.05. ***p value vs. primary tumor (PT) < 0.001